- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03929159
Correlating MicroRNA Changes With Sepsis Outcomes
Profile of miRNA Changes in Sepsis and Surgical Trauma
Study Overview
Detailed Description
PRIMARY OBJECTIVES:
I. To examine whether the cellular and viral micro ribonucleic acid (miRNA) changes in plasma and peripheral mononuclear blood cells (PMNCs) correlate with the diagnosis and outcome of sepsis.
SECONDARY OBJECTIVES:
I. To distinguish systemic inflammatory response syndrome (SIRS) without infection from sepsis and septic shock.
OUTLINE: Patients are assigned to 1 of 2 groups.
GROUP A: Patients undergo blood specimen collection at baseline (before surgery), the day after surgery, either the day of hospital discharge or the day of sepsis diagnosis, and 6 days after the baseline blood draw if still hospitalized.
GROUP B: Patients undergo blood specimen collection at baseline (day of sepsis diagnosis), the day after baseline, and on day 7 from baseline if still hospitalized.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Sai-Ching J. Yeung
- Phone Number: 713-745-9911
- Email: syeung@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- M D Anderson Cancer Center
-
Contact:
- Sai-Ching J. Yeung
- Phone Number: 713-745-9911
-
Principal Investigator:
- Sai-Ching J. Yeung
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Electively scheduled for surgical operation that require general anesthesia and expected duration of hospitalization of longer than one day (for patients in Perioperative Evaluation & Management [POEM]) or high clinical suspicion of sepsis by the emergency physician (for patients in emergency center)
- Ability to give informed consent. If the patient is incapacitated and unable to give informed consent, the next-of-kin or a person who has the power of attorney must be present for informed consent.
For patients in the emergency center only, two or more of the following SIRS criteria:
- Leukocytes > 12,000/mm^3 or < 4,000/mm^3 or > 10% immature (band) forms, provided that no filgrastim or pegfilgrastim was administered within 30 days and no leukemia
- Heart rate > 90 beats/minute (min)
- Respiratory rate > 20 breaths/min or partial pressure of carbon dioxide (CO2) < 32 mmHg
- Oral temperature > 38 degrees Celsius (C) or < 36 degrees C or axillary temperature > 37 degrees C or < 35 degrees C
Exclusion Criteria:
- Inability to give informed consent or a person who has power of attorney for medical decision is not available
- Being moribund (for patients in emergency center) or cancellation of surgery (for patients in POEM)
- Active "Do Not Resuscitate" or "Do Not Intubate" order
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group A (biospecimen collection)
Patients undergo blood specimen collection at baseline (before surgery), the day after surgery, either the day of hospital discharge or the day of sepsis diagnosis, and 6 days after the baseline blood draw if still hospitalized.
|
Undergo blood biospecimen collection
|
Group B (biospecimen collection)
Patients undergo blood specimen collection at baseline (day of sepsis diagnosis), the day after baseline, and on day 7 from baseline if still hospitalized.
|
Undergo blood biospecimen collection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in cellular and viral micro ribonucleic acids (miRNAs)
Time Frame: Baseline up to day 1
|
For each of the cellular and viral miRNAs, samples from patients with sepsis versus (vs.) patients with systemic inflammatory response syndrome (SIRS) without sepsis vs. patients presenting for pre-op evaluation (reference group without SIRS or sepsis) will be compared by one-way analysis of variance.
Will compare the miRNA expression intergroup differences.
|
Baseline up to day 1
|
7-day mortality rate
Time Frame: Baseline up to day 7
|
Will be correlated with miRNA changes.
Will compare the changes of the miRNAs from baseline to day 1 between the patients who were still alive 7 days after diagnosis of sepsis and those who died within 7 days of sepsis diagnosis.
|
Baseline up to day 7
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
T and B cells immune phenotypes
Time Frame: Up to 2 years
|
Up to 2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sai-Ching J Yeung, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018-0757 (Other Identifier: M D Anderson Cancer Center)
- NCI-2019-00833 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- R01GM122775 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Septicemia
-
University Hospital, BordeauxAquitaine MicrobiologieCompletedSepticemia in HemodialysisFrance
-
National Taiwan University HospitalCompletedMethicillin-resistant Staphylococcus Aureus SepticemiaTaiwan
-
Miquel PujolInstitut d'Investigació Biomèdica de Bellvitge; Instituto de Salud Carlos IIITerminatedMethicillin Susceptible Staphylococcus Aureus SepticemiaSpain
-
Makerere UniversityCentre For International HealthUnknown
-
McGill University Health Centre/Research Institute...CompletedBacteremia | Methicillin Susceptible Staphylococcus Aureus SepticemiaCanada
-
Todd C. Lee MD MPH FIDSARecruitingStaphylococcus Aureus Bacteremia | Staphylococcus Aureus Endocarditis | Staphylococcus Aureus Septicemia | Staphylococcal SepsisCanada
-
Centre Hospitalier Universitaire DijonRecruiting
-
Hadassah Medical OrganizationCompleted
-
Chiang Mai UniversityUnknown
-
Magnolia Medical Technologies, Inc.CompletedSepticemiaUnited States
Clinical Trials on Biospecimen Collection
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingBreast Adenocarcinoma | HER2-Positive Breast CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditionsUnited States, Puerto Rico
-
Mayo ClinicRecruitingEarly Stage Breast Carcinoma | Chemotherapy-Related Nausea and/or VomitingUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruiting
-
Thomas Jefferson UniversityNational Cancer Institute (NCI)Recruiting
-
LLS PedAL Initiative, LLCNational Cancer Institute (NCI); Children's Oncology GroupRecruitingAcute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Myeloid Leukemia Associated With Down Syndrome | Mixed Phenotype Acute Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy | Myelodysplastic Syndrome Post Cytotoxic TherapyUnited States, Canada, Australia, Puerto Rico, New Zealand
-
Mayo ClinicRecruitingMetastatic Breast Cancer | HER2-negative Breast Cancer | Hormone-receptor-positive Breast CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterRecruitingCholangiocarcinoma | Malignant Digestive System NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterGuardant Health, Inc.RecruitingColorectal CarcinomaUnited States